Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,708 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Safety, and Tolerability Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 22, 2026, 4:09 PM EDT
No Longer Available No phase listed Expanded access

Extension Study of Drisapersen in DMD Subjects

NCT02636686
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Drisapersen
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Jul 22, 2026, 4:09 PM EDT
Recruiting Phase 1 Interventional

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

NCT07242469
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
MK-1403 + additive coformulation, Placebo + additive coformulation
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 4:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

NCT04691154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions
L606 inhalation suspension
Combination Product
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 4:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 4:09 PM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

NCT03895996
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AVT001, Placebo
Drug · Other
Lead sponsor
Avotres Inc.
Industry
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

NCT00640042
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate extended release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
378
States / cities
Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 22, 2026, 4:09 PM EDT
Active, not recruiting Phase 3 Interventional

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

NCT04285086
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
Ropeginterferon alfa-2b, Anagrelide
Biological · Drug
Lead sponsor
PharmaEssentia
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
4
States / cities
Scottsdale, Arizona • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Safety, Tolerability, & Pharmacokinetics of K-285 Compared With Indomethacin Capsule in Healthy Adults

NCT03712241
View directory record Official record
Conditions
Healthy
Interventions
K-285, Indomethacin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266
View directory record Official record
Conditions
Myelodysplastic Syndrome, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Jul 22, 2026, 4:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

NCT05972629
View directory record Official record
Conditions
Phenylketonuria
Interventions
SAR444836
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults

NCT01739231
View directory record Official record
Conditions
Diarrhea
Interventions
ACE527, dmLT, CeraVacx placebo, H10407 challenge strain
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 50 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Jul 22, 2026, 4:09 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

NCT04444050
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986331, Placebo, Matching BMS-986331
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 22, 2026, 4:09 PM EDT
Recruiting Phase 2 Interventional

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420
View directory record Official record
Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)
Interventions
Efgartigimod IV, Empasiprubart IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Carlsbad, California • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 4:09 PM EDT
Terminated Phase 2 Interventional

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

NCT00973024
View directory record Official record
Conditions
Low Back Pain, Low Back Pain, Recurrent
Interventions
JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg, JNJ-42160443 10 mg, Matching Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

NCT05411588
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-07275315, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Early Phase 1 Interventional Results available

Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine

NCT05076370
View directory record Official record
Conditions
Addiction
Interventions
CBD Day 1, CBD Day 2, CBD Day 3
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 22, 2026, 4:09 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

NCT07290283
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD3974, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

NCT02185053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CPC-201
Drug
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Industry
Eligibility
50 Years to 79 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses

NCT01998646
View directory record Official record
Conditions
Pharmacokinetics of ASP4058, Healthy Subjects, Food Effect of ASP4058
Interventions
ASP4058, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Miami, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 1, 2013 · Synced Jul 22, 2026, 4:09 PM EDT
Terminated Phase 3 Interventional Results available

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

NCT05643170
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Jul 22, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

NCT02313883
View directory record Official record
Conditions
Periodontitis
Interventions
PerioSept(r)
Drug
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 74 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
4
States / cities
Fullerton, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 22, 2026, 4:09 PM EDT